SNY will commercialize NVAX’s existing COVID vaccine and will develop a combination COVID/flu vaccine incorporating NVAX’s “Matrix-M” adjuvant technology.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.